Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.

Hankosky ER, Lebrec J, Lee CJ, Dimitriadis GK, Jouravskaya I, Stefanski A, Garvey WT

Diabetes, obesity & metabolism29 Sept 2025Cited by 14 (Europe PMC)

PMID41017451PMCIDPMC12587230DOI10.1111/dom.70143PepBankPUB-41017451

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity and prediabetes, tirzepatide 5 mg reduced predicted 10-year ASCVD risk (ACC/AHA) by 4.6% at week 176, while risk rose with placebo.
In plain wordsIn adults with obesity and prediabetes, tirzepatide 5 mg lowered predicted heart disease risk, while it rose with placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year ASCVD risk, ACC/AHA equations (5 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
5 mg · 176 weeksAs given in this study (human).
Measurements
Mean percent change in ASCVD risk (ACC/AHA)
−4.6%
tirzepatide 5 mg
Mean percent change in ASCVD risk (ACC/AHA)
57.9%
placebo
Source sentences
Summary
Mean percent change from baseline to week 176 in predicted ASCVD risk score was greater in tirzepatide-treated groups using the ACC/AHA (5 mg: -4.6%; 10 mg: -7.5%; 15 mg: -9.2%) and PREVENT risk equations (5 mg: -3.7%; 10 mg: -6.3%; 15 mg: -8.8%) versus increased risk in placebo (57.9% and 40.5%, re…
1 context sentence(design, population, supporting numbers)
Summary · context
In the trial, participants with obesity and prediabetes at baseline were randomly assigned to once weekly tirzepatide (5/10/15 mg) or placebo for 176 weeks of treatment.
Report a problemFND-4101745101
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity and prediabetes, tirzepatide 10 mg reduced predicted 10-year ASCVD risk (ACC/AHA) by 7.5% at week 176, while risk rose with placebo.
In plain wordsIn adults with obesity and prediabetes, tirzepatide 10 mg lowered predicted heart disease risk, while it rose with placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year ASCVD risk, ACC/AHA equations (10 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
10 mg · 176 weeksAs given in this study (human).
Measurements
Mean percent change in ASCVD risk (ACC/AHA)
−7.5%
tirzepatide 10 mg
Mean percent change in ASCVD risk (ACC/AHA)
57.9%
placebo
Source sentences
Summary
Mean percent change from baseline to week 176 in predicted ASCVD risk score was greater in tirzepatide-treated groups using the ACC/AHA (5 mg: -4.6%; 10 mg: -7.5%; 15 mg: -9.2%) and PREVENT risk equations (5 mg: -3.7%; 10 mg: -6.3%; 15 mg: -8.8%) versus increased risk in placebo (57.9% and 40.5%, re…
1 context sentence(design, population, supporting numbers)
Summary · context
In the trial, participants with obesity and prediabetes at baseline were randomly assigned to once weekly tirzepatide (5/10/15 mg) or placebo for 176 weeks of treatment.
Report a problemFND-4101745102
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity and prediabetes, tirzepatide 15 mg reduced predicted 10-year ASCVD risk (ACC/AHA) by 9.2% at week 176, while risk rose with placebo.
In plain wordsIn adults with obesity and prediabetes, tirzepatide 15 mg lowered predicted heart disease risk, while it rose with placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year ASCVD risk, ACC/AHA equations (15 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
15 mg · 176 weeksAs given in this study (human).
Measurements
Mean percent change in ASCVD risk (ACC/AHA)
−9.2%
tirzepatide 15 mg
Mean percent change in ASCVD risk (ACC/AHA)
57.9%
placebo
Source sentences
Summary
Mean percent change from baseline to week 176 in predicted ASCVD risk score was greater in tirzepatide-treated groups using the ACC/AHA (5 mg: -4.6%; 10 mg: -7.5%; 15 mg: -9.2%) and PREVENT risk equations (5 mg: -3.7%; 10 mg: -6.3%; 15 mg: -8.8%) versus increased risk in placebo (57.9% and 40.5%, re…
1 context sentence(design, population, supporting numbers)
Summary · context
In the trial, participants with obesity and prediabetes at baseline were randomly assigned to once weekly tirzepatide (5/10/15 mg) or placebo for 176 weeks of treatment.
Report a problemFND-4101745103
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity and prediabetes, tirzepatide 5 mg reduced predicted 10-year ASCVD risk (PREVENT) by 3.7% at week 176, while risk rose with placebo.
In plain wordsIn adults with obesity and prediabetes, tirzepatide 5 mg lowered predicted heart disease risk, while it rose with placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year ASCVD risk, PREVENT equations (5 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
5 mg · 176 weeksAs given in this study (human).
Measurements
Mean percent change in ASCVD risk (PREVENT)
−3.7%
tirzepatide 5 mg
Mean percent change in ASCVD risk (PREVENT)
40.5%
placebo
Source sentences
Summary
Mean percent change from baseline to week 176 in predicted ASCVD risk score was greater in tirzepatide-treated groups using the ACC/AHA (5 mg: -4.6%; 10 mg: -7.5%; 15 mg: -9.2%) and PREVENT risk equations (5 mg: -3.7%; 10 mg: -6.3%; 15 mg: -8.8%) versus increased risk in placebo (57.9% and 40.5%, re…
1 context sentence(design, population, supporting numbers)
Summary · context
In the trial, participants with obesity and prediabetes at baseline were randomly assigned to once weekly tirzepatide (5/10/15 mg) or placebo for 176 weeks of treatment.
Report a problemFND-4101745104
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity and prediabetes, tirzepatide 10 mg reduced predicted 10-year ASCVD risk (PREVENT) by 6.3% at week 176, while risk rose with placebo.
In plain wordsIn adults with obesity and prediabetes, tirzepatide 10 mg lowered predicted heart disease risk, while it rose with placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year ASCVD risk, PREVENT equations (10 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
10 mg · 176 weeksAs given in this study (human).
Measurements
Mean percent change in ASCVD risk (PREVENT)
−6.3%
tirzepatide 10 mg
Mean percent change in ASCVD risk (PREVENT)
40.5%
placebo
Source sentences
Summary
Mean percent change from baseline to week 176 in predicted ASCVD risk score was greater in tirzepatide-treated groups using the ACC/AHA (5 mg: -4.6%; 10 mg: -7.5%; 15 mg: -9.2%) and PREVENT risk equations (5 mg: -3.7%; 10 mg: -6.3%; 15 mg: -8.8%) versus increased risk in placebo (57.9% and 40.5%, re…
1 context sentence(design, population, supporting numbers)
Summary · context
In the trial, participants with obesity and prediabetes at baseline were randomly assigned to once weekly tirzepatide (5/10/15 mg) or placebo for 176 weeks of treatment.
Report a problemFND-4101745105
06HumanRandomized controlled trialEfficacy outcome
In adults with obesity and prediabetes, tirzepatide 15 mg reduced predicted 10-year ASCVD risk (PREVENT) by 8.8% at week 176, while risk rose with placebo.
In plain wordsIn adults with obesity and prediabetes, tirzepatide 15 mg lowered predicted heart disease risk, while it rose with placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year ASCVD risk, PREVENT equations (15 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
15 mg · 176 weeksAs given in this study (human).
Measurements
Mean percent change in ASCVD risk (PREVENT)
−8.8%
tirzepatide 15 mg
Mean percent change in ASCVD risk (PREVENT)
40.5%
placebo
Source sentences
Summary
Mean percent change from baseline to week 176 in predicted ASCVD risk score was greater in tirzepatide-treated groups using the ACC/AHA (5 mg: -4.6%; 10 mg: -7.5%; 15 mg: -9.2%) and PREVENT risk equations (5 mg: -3.7%; 10 mg: -6.3%; 15 mg: -8.8%) versus increased risk in placebo (57.9% and 40.5%, re…
1 context sentence(design, population, supporting numbers)
Summary · context
In the trial, participants with obesity and prediabetes at baseline were randomly assigned to once weekly tirzepatide (5/10/15 mg) or placebo for 176 weeks of treatment.
Report a problemFND-4101745106
07HumanRandomized controlled trialEfficacy outcome
In adults with obesity and prediabetes, tirzepatide 5 mg reduced the predicted 10-year type 2 diabetes risk score (CMDS) by 17.0% at week 176, versus 4.3% with placebo.
In plain wordsIn adults with obesity and prediabetes, tirzepatide 5 mg lowered predicted diabetes risk more than placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year type 2 diabetes risk, CMDS (5 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
5 mg · 176 weeksAs given in this study (human).
Measurements
Absolute change in T2D risk (CMDS)
−17%
tirzepatide 5 mg
Absolute change in T2D risk (CMDS)
−4.3%
placebo
Source sentences
Summary
Mean absolute change in T2D risk scores from baseline to week 176 using Cardiometabolic Disease Staging (CMDS) was greater in tirzepatide-treated groups (5 mg: -17.0%; 10 mg: -19.6%; 15 mg: -19.5%) versus placebo (-4.3%, p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In the trial, participants with obesity and prediabetes at baseline were randomly assigned to once weekly tirzepatide (5/10/15 mg) or placebo for 176 weeks of treatment.
Report a problemFND-4101745107
08HumanRandomized controlled trialEfficacy outcome
In adults with obesity and prediabetes, tirzepatide 10 mg reduced the predicted 10-year type 2 diabetes risk score (CMDS) by 19.6% at week 176, versus 4.3% with placebo.
In plain wordsIn adults with obesity and prediabetes, tirzepatide 10 mg lowered predicted diabetes risk more than placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year type 2 diabetes risk, CMDS (10 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
10 mg · 176 weeksAs given in this study (human).
Measurements
Absolute change in T2D risk (CMDS)
−19.6%
tirzepatide 10 mg
Absolute change in T2D risk (CMDS)
−4.3%
placebo
Source sentences
Summary
Mean absolute change in T2D risk scores from baseline to week 176 using Cardiometabolic Disease Staging (CMDS) was greater in tirzepatide-treated groups (5 mg: -17.0%; 10 mg: -19.6%; 15 mg: -19.5%) versus placebo (-4.3%, p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In the trial, participants with obesity and prediabetes at baseline were randomly assigned to once weekly tirzepatide (5/10/15 mg) or placebo for 176 weeks of treatment.
Report a problemFND-4101745108
09HumanRandomized controlled trialEfficacy outcome
In adults with obesity and prediabetes, tirzepatide 15 mg reduced the predicted 10-year type 2 diabetes risk score (CMDS) by 19.5% at week 176, versus 4.3% with placebo.
In plain wordsIn adults with obesity and prediabetes, tirzepatide 15 mg lowered predicted diabetes risk more than placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted 10-year type 2 diabetes risk, CMDS (15 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
15 mg · 176 weeksAs given in this study (human).
Measurements
Absolute change in T2D risk (CMDS)
−19.5%
tirzepatide 15 mg
Absolute change in T2D risk (CMDS)
−4.3%
placebo
Source sentences
Summary
Mean absolute change in T2D risk scores from baseline to week 176 using Cardiometabolic Disease Staging (CMDS) was greater in tirzepatide-treated groups (5 mg: -17.0%; 10 mg: -19.6%; 15 mg: -19.5%) versus placebo (-4.3%, p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In the trial, participants with obesity and prediabetes at baseline were randomly assigned to once weekly tirzepatide (5/10/15 mg) or placebo for 176 weeks of treatment.
Report a problemFND-4101745109

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.

Summary

Results from this study9

Version history

Subjects

Publication types

MeSH terms

Keywords